REO-10: a phase I study of intravenous reovirus and docetaxel in patients with advanced cancer.
about
Immune recruitment and therapeutic synergy: keys to optimizing oncolytic viral therapy?Cell carriage, delivery, and selective replication of an oncolytic virus in tumor in patientsClinical development of reovirus for cancer therapy: An oncolytic virus with immune-mediated antitumor activityMoving oncolytic viruses into the clinic: clinical-grade production, purification, and characterization of diverse oncolytic virusesEvidence for Oncolytic Virotherapy: Where Have We Got to and Where Are We Going?Potential for Improving Potency and Specificity of Reovirus Oncolysis with Next-Generation Reovirus VariantsGoing viral: a review of replication-selective oncolytic adenovirusesOncolytic virotherapy for human malignant mesothelioma: recent advancesChemovirotherapy: combining chemotherapeutic treatment with oncolytic virotherapyCancer immunotherapy via combining oncolytic virotherapy with chemotherapy: recent advancesOncolytic virotherapy for pediatric malignancies: future prospectsHarnessing the Power of Onco-Immunotherapy with Checkpoint InhibitorsSerotype-Specific Killing of Large Cell Carcinoma Cells by Reovirus.A phase I trial of single-agent reolysin in patients with relapsed multiple myelomaSynergistic effects of oncolytic reovirus and docetaxel chemotherapy in prostate cancer.Reovirus exerts potent oncolytic effects in head and neck cancer cell lines that are independent of signalling in the EGFR pathway.A phase I trial and viral clearance study of reovirus (Reolysin) in children with relapsed or refractory extra-cranial solid tumors: a Children's Oncology Group Phase I Consortium reportCytokine conditioning enhances systemic delivery and therapy of an oncolytic virus.The combination of intravenous Reolysin and gemcitabine induces reovirus replication and endoplasmic reticular stress in a patient with KRAS-activated pancreatic cancer.Naturally occurring reoviruses for human cancer therapy.Phase II trial of intravenous administration of Reolysin(®) (Reovirus Serotype-3-dearing Strain) in patients with metastatic melanoma.Oncolytic reovirus synergizes with chemotherapeutic agents to promote cell death in canine mammary gland tumorReovirus-mediated cytotoxicity and enhancement of innate immune responses against acute myeloid leukemia.Combination Therapy With Reovirus and Anti-PD-1 Blockade Controls Tumor Growth Through Innate and Adaptive Immune ResponsesPhase I trial of cyclophosphamide as an immune modulator for optimizing oncolytic reovirus delivery to solid tumors.Synergistic cytotoxicity of oncolytic reovirus in combination with cisplatin-paclitaxel doublet chemotherapy.Reovirus in cancer therapy: an evidence-based reviewReolysin is a novel reovirus-based agent that induces endoplasmic reticular stress-mediated apoptosis in pancreatic cancer.Oncolytic reovirus in combination with chemotherapy in metastatic or recurrent non-small cell lung cancer patients with KRAS-activated tumors.Reovirus: a targeted therapeutic--progress and potential.Cytotoxic and immune-mediated killing of human colorectal cancer by reovirus-loaded blood and liver mononuclear cellsOncolytic reovirus type 3 (Dearing) as a novel therapy in head and neck cancer.Multispectral imaging: a review of its technical aspects and applications in anatomic pathology.Oncolytic virus therapies.Junctional adhesion molecule-A is overexpressed in advanced multiple myeloma and determines response to oncolytic reovirus.The oncolytic virus, pelareorep, as a novel anticancer agent: a review.HIF-1α downregulation and apoptosis in hypoxic prostate tumor cells infected with oncolytic mammalian orthoreovirus.Asynchronous leptomeningeal carcinomatosis from pancreatic cancer: a case report and review of the literature.Precise scheduling of chemotherapy primes VEGF-producing tumors for successful systemic oncolytic virotherapy.Randomized phase IIB evaluation of weekly paclitaxel versus weekly paclitaxel with oncolytic reovirus (Reolysin®) in recurrent ovarian, tubal, or peritoneal cancer: An NRG Oncology/Gynecologic Oncology Group study.
P2860
Q24596171-EDB8A942-04EF-4546-B207-7403444B5971Q24617027-E3E17DD7-0E31-4283-B478-BCC00B6B1C77Q26750568-FF383147-2064-42CC-B7EA-BDBEB24A40A7Q26752807-208303CD-67B5-48FD-8686-EB8FF848AE69Q26775030-75F118BA-9559-433C-93E2-374AE9FB2C64Q26775033-7F99B50E-8F30-46A6-AFCF-38BB6F19F22CQ26797520-73A2DD44-083C-438B-ACA1-AA5F29D4F37FQ26826590-0D5951C9-C378-460D-ACA9-2F2DB64B9B43Q26852345-F5395071-FEFB-41AC-ABAD-4A094B59481EQ26863779-625D9DE8-F71B-4707-B8C1-7977D7EE63B9Q28069358-08A2C1C3-0318-4E14-9494-8E7D1C4C0901Q28086999-04B0D4F3-A674-4AF0-B8C8-9DC96AD695F0Q32183285-F6486EDB-0B41-4A30-A451-DF3F9A1739F3Q33418048-42CCBBD4-D9AE-41EB-9EA7-013203D7883BQ33924515-F87F1198-4031-4675-A093-8C1F9AB2AB2AQ34393001-11EA0381-D467-403F-A326-6672BC35F27CQ35224368-29ABC356-2C46-418D-9B4B-11AC67BCB855Q35596563-FE7C99FA-53F4-4473-9386-9B291C3879C9Q35686522-89C0EA9A-3CAA-4EE9-AFD5-4ED8CD2C17A7Q36078485-2D19CF2B-67E1-4BC2-A2E5-A6A9296A72CCQ36298608-A0D10C70-9987-4F2E-A989-E8A92686DF94Q36390114-0CFAFDEC-5DF7-4EAF-924F-23945A53D21DQ36574519-AA895A6B-369B-4CE3-89DD-C2196DB9FDB1Q36582819-D9680F17-83FD-43C7-B6F5-68BE58A8FC35Q36766032-01C2CCCD-E025-45D3-B90E-39449F6DDABFQ36766052-678A5959-8150-4A3A-80BD-4160E3126A2EQ37031909-DB9A8856-B2C3-4AC3-8AF2-F1A4CB977142Q37062074-0851B87A-A61B-40BF-B964-C32006C9658BQ37347236-BE6FDC0B-4F22-48D6-8BED-78F8F246FCCBQ37360608-305A73E1-1F63-454A-9585-9DD0BE0A0EAAQ37477574-D4335867-06DF-42DF-A34B-1BF8152C8CF3Q38058884-08853587-5713-48CE-8B06-91C622BDF2B6Q38152999-8E6BD4C7-254A-4CDE-BD3E-1CADDFCC8A95Q38162950-3D7FA877-C3FE-4D8D-88A1-FA6B341EC46BQ38315523-C8F625D8-DFD2-47A9-B126-52682F0A704DQ38360781-896DBCF1-1141-431B-8340-3CB772AAE1F1Q38458133-A84FDDFC-397A-458C-AAF6-1AF7B2776954Q38548938-A0A765DB-56AC-4624-884E-9F4D55C4C8D8Q38647883-56CB59E6-9BA7-4032-A5A1-BA0F4DEEE484Q38653084-940DC60F-B267-424C-A961-5E5E97730B5C
P2860
REO-10: a phase I study of intravenous reovirus and docetaxel in patients with advanced cancer.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 06 October 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
REO-10: a phase I study of int ...... patients with advanced cancer.
@en
REO-10: a phase I study of int ...... patients with advanced cancer.
@en-gb
REO-10: a phase I study of int ...... patients with advanced cancer.
@nl
type
label
REO-10: a phase I study of int ...... patients with advanced cancer.
@en
REO-10: a phase I study of int ...... patients with advanced cancer.
@en-gb
REO-10: a phase I study of int ...... patients with advanced cancer.
@nl
prefLabel
REO-10: a phase I study of int ...... patients with advanced cancer.
@en
REO-10: a phase I study of int ...... patients with advanced cancer.
@en-gb
REO-10: a phase I study of int ...... patients with advanced cancer.
@nl
P2093
P2860
P1476
REO-10: a phase I study of int ...... patients with advanced cancer.
@en
P2093
Andrew Protheroe
Charles Comins
Christine M White
David E Cohn
Gerard Nuovo
Hardev S Pandha
James Spicer
Karl L Mettinger
Katie Twigger
Kevin J Harrington
P2860
P304
P356
10.1158/1078-0432.CCR-10-1233
P407
P50
P577
2010-10-06T00:00:00Z